Results 131 to 140 of about 25,852 (227)

Evaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma models

open access: yesInternational Journal of Nanomedicine, 2016
Deborah Michel,1 Waleed Mohammed-Saeid,1 Heather Getson,1 Caitlin Roy,1 Masoomeh Poorghorban,1 Jackson M Chitanda,2 Ronald Verrall,2 Ildiko Badea1 1Drug Design and Discovery Research Group, College of Pharmacy and Nutrition, 2Department of Chemistry ...
Michel D   +7 more
doaj  

Intraperitoneal chemotherapy with cisplatin and melphalan.

open access: yes, 1988
Cisplatin and melphalan given ip exert a synergistic therapeutic effect against ascitic P388 leukemia in mice and have different dose-limiting toxic effects as well as favorable pharmacokinetic characteristics in ip phase I studies. We gave a total of 98
Sculier, Jean-Paul   +9 more
core  

New melphalan derivatives for the treatment of retinoblastoma in combination with thermotherapy

open access: yes
Of the different modalities used to treat retinoblastoma, a chemothermotherapeutic regimen combining carboplatin and thermotherapy (also termed focal therapy), and the application of melphalan as a monotherapy, are particularly successful.
Munier, Francis L   +22 more
core   +1 more source

Plenary Abstracts Session & Oral Presentations

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Preclinical Studies of the Melphalan Prodrug J1 for Cancer Therapy [Elektronisk resurs]

open access: yes, 2007
J1 (L-melphalanyl-L-p-fluorophenylalanyl ethyl ester) is a dipeptide derivative of the alkylating agent melphalan with increased cytotoxicity. In this thesis the preclinical pharmacology of J1 has been characterized.Our results show that J1 rapidly ...
Larsson, Rolf   +3 more
core  

Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysis. [PDF]

open access: yesFront Oncol
Morecroft R   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy